Clinical Trial Update: Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice

View source ↗

Summary

An observational study assessing persistence on Bafiertam (dimethyl fumarate) in relapsing-remitting multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BAFIERTAM (MONOMETHYL FUMARATE)

Snippet

Sponsor: Banner Life Sciences LLC | Conditions: Relapsing Remitting Multiple Sclerosis | Status: TERMINATED